Safeplus International Holdings Ltd. (ACAI)

[palacian]

grapeman, biophan never was a stent company. they have/had
patents that improve stent visibility under mri.

they have a royality agreement with boston scientific and
sold the rest of the technology to medtronic. biph's only
forward looking viability is the bsx contract and a slim
20% of myo cardio care, a private company who purchased the
technology from biph. myo is still in development stage
and far from producing anything for a long time.

unless bsx makes market with biph add-on tech, they only pay
$250k/y for the right to keep the tech under their wraps.
maybe that is where they want it to stay.

interesting article you referenced. at this time,
only the shadow knows.

gltu